Annual revenue was KRW 5.06 billion in 2022, KRW 4.95 billion in 2023 (down 2.2% year on year), KRW 34 billion in 2024 (up 586.9% year on year), and KRW 99.8 billion in 2025 (up 193.6% year on year). Revenue rose for two consecutive years from 2024 through 2025, and 2025 was the largest year of 2022 to 2025.
The operating loss widened from KRW 28.6 billion in 2022 to KRW 32.7 billion in 2023, narrowed to an operating loss of KRW 2.73 billion in 2024, and turned into an operating profit of KRW 52.1 billion in 2025. The operating margin moved from -8.0% in 2024 to 52.2% in 2025.
Net income attributable to controlling shareholders turned to KRW 877 million in 2024 and reached KRW 52.3 billion in 2025, up 5,871.6% year on year. Net income including non-controlling interests was KRW 54.4 billion in 2025 and is a different figure from net income attributable to controlling shareholders.
According to company disclosures, annual royalty income rose each year, from KRW 1.07 billion in 2022 and KRW 1.29 billion in 2023 to KRW 2.64 billion in 2024 and KRW 7.53 billion in 2025. Full-year 2025 revenue reflected lazertinib milestones and royalties and the upfront payment from the Sanofi deal.
By quarter, the fourth quarter of 2025 was the largest of the reported quarters, with revenue of KRW 78.9 billion and operating profit of KRW 61.4 billion. The first quarter of 2026 returned to revenue of KRW 3.65 billion and an operating loss of KRW 9.99 billion.
The second quarter of 2026 recorded revenue of KRW 52.6 billion and operating profit of KRW 38.7 billion as the cevidoplenib upfront was recognized. The third quarter of 2026 recorded revenue of KRW 6.57 billion and an operating loss of KRW 6.69 billion, with revenue down 26.6% year on year and the loss widening.
Third-quarter R&D spending of KRW 8.5 billion was up 60% year on year, which added pressure alongside lower revenue.